Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release.
1992.-We evaluated whether the brain kallikrein-kinin system plays a role in the regulation of adrenocorticotropin (ACTH) release in rats. Intracerebroventricular (icv) injection of bradykinin (0.24 nmol) increased plasma immunoreactive ACTH (irACTH) levels (from 93 & 4 to 200 t 12 pg/ml, P c 0.01). This effect was prevented by icv kinin antagonist at 15.4 nmol/ h (from 98 & 5 to 108 t 6 pg/ml; not significant). The antagonist did not alter the increase in plasma irACTH levels induced by icv corticotropin-releasing factor (CRF), arginine vasopressin, or prostaglandin Ez. Melittin (7 nmol/h icv) increased plasma irACTH from 95 & 4 to 268 t 7 pg/ml (P < 0.01). This effect was prevented by icv kinin antagonist (15.4 nmol/h), kallikrein antibodies (13 pmol/h), or indomethacin (0.28 mmol/h). ACTH response to melittin was not altered by antagonists of CRF or vasopressin. Intra-arterial injection of insulin (0.3 IU/kg body wt) reduced plasma glucose levels to a similar extent in rats given icv kinin antagonist or vehicle; the ACTH response to insulin-induced hypoglycemia was slightly less in rats given kinin antagonist than in those given vehicle (55 t 5 vs. 86 t 4 pg/ml, P < 0.05). The brain kallikrein-kinin system may play a role in the regulation of ACTH secretion in stimulated conditions. melittin; pituitary ADRENOCORTICOTROPIN (ACTH) release from adenohypophysis is controlled by multiple hypothalamic, neurohypophysial, and peripheral regulatory factors. Putative regulators of ACTH secretion include corticotropinreleasing factor (CRF) (32) , arginine vasopressin (AVP) (9), epinephrine (8), angiotensin II (ANG II) (7), and prostaglandins (PGs) (3 1) . The kallikrein-kinin system, which is present with all its components in various areas of the brain (3, 11, 21) , may participate in the regulation of ACTH secretion. Powers and Nasjletti (24) found that glandular-like kallikrein activity exists in the pituitary gland, a major site of proopiomelanocortin (POMC) gene expression and secretion. In the anterior pituitary, glandular kallikrein is X8 times higher in female than in male rats (25), and its gene expression is under estrogen control (2) . Localization of glandular kallikrein in lactotrophs of the rat anterior pituitary suggests that the function of kallikrein in this region is linked to prolactin in some fashion, possibly as a prolactin-processing protease (34) . In the intermediate lobe, glandular kallikrein has been localized in melanotrophs, where it is regulated in a parallel fashion with POMC by dopaminergic compounds (23, 26).
Because glandular kallikrein belongs to a family of endopeptidases involved in the trypsin-like processing of specific prohormone precursors (4, 17, 19) , pituitary kallikrein might cleave POMC protein to POMC-derived peptides [ACTH, endorphins, and melanocyte-stimulating hormone (MSH)]. On the other hand, kallikrein cleaves kininogen to generate kinins that may act as neuromodulators or neurotransmitters to influence the secretion of POMC-derived peptides. An anatomic basis in support of that hypothesis is provided by the presence of a bradykinin-like substance in the brain (11, 21), particularly at the level of the periventricular and dorsomedial nuclei of the hypothalamus (3) . In addition, bradykinin is able to stimulate the release of ACTH and ,&endorphin in vitro as well as in vivo (10, 15, 18) .
The general purpose of the present study was to evaluate the role of the endogenous kallikrein-kinin system in the regulation of ACTH secretion in the female rat. To address this issue we evaluated the effect of the intracerebroventricular (icv) administration of either a competitive antagonist of bradykinin or kallikrein affinity-purified antibodies against rat glandular kallikrein on plasma ACTH levels as follows: 1) under basal conditions; 2) during the icv infusion of melittin, a peptide able to enhance dog and rat cerebrospinal fluid (CSF) kininogenase activity and kinin levels (30, 36) and able to stimulate ACTH and P-endorphin release from rat anterior pituitary in vitro (12); and 3) during insulininduced hypoglycemia, a well-known stimulus of ACTH secretion (22).
MATERIALS AND METHODS

Materials
Bradykinin, the kinin antagonist
(where Hyp is L-4-hydroxyproline and Thi is p-2-thienyl-L-alanine), rat CRF, the CRF antagonist a-helical CRF-(9-41), AVP, PGE2, and melittin were purchased from Peninsula Laboratories (Merseyside, UK); the vasopressin antagonist des-GlyQ%mercapto-/3,p-cyclopentamethylenepropionyl,0-et-Tyr2,Val4,Ar~]vasopressin and estradiol benzoate were purchased from Sigma Chemical (St. Louis, MO); indomethacin (meglumine salt) was purchased from Chiesi Pharmaceutical (Rome, Italy); insulin (Actrapid HM) was purchased from Novo Nordisk (Bagsvaerd, Denmark). Kallikrein affinity-purified sheep anti-rat glandular kallikrein antibodies (35) were kindly provided by Dr. Julie Chao, University of South Carolina. The ability of antibodies to inhibit the activity of rat glandular kallikrein was preliminarily tested on the synthetic substrate D-Val-Leu-Arg-p-nitroaniline in 0. Female Wistar rats (Morini, Milan, Italy) weighing 200-220 g were housed at constant room temperature with a 12: 12-h light-dark cycle and had free access to water and rat Chow. Under ether anesthesia, rats underwent bilateral ovariectomy and then were injected subcutaneously with 0.05 pmol estradiol benzoate (in 100 ~1 sesame oil) twice a week. The female rat was chosen as a model to study the physiological role of the kallikrein-kinin system, according to the finding that a higher kininogenase activity is present in the CSF of female compared with male rats; it is decreased by ovariectomy and restored to normal by estrogen (Madeddu, unpublished observations) . In the present study, ovariectomy and hormonal replacement with estradiol benzoate were performed to reduce variability in hormonal responses that may occur as a consequence of changes in the expression of hypothalamic and pituitary receptors during the rat estrous cycle (5) . In preliminary experiments we found that mean plasma estradiol levels did not differ in 2-wk ovariectomized female rats given estradiol benzoate and in intact female rats (32 t 3 vs. 38 t 12 pg/ml, respectively), although a wider variability was observed in the latter group. Two weeks after ovariectomy, a Z-gauge stainless steel cannula (15 mm in length, bent at a 90" angle) was implanted stereotaxically into each lateral cerebral ventricle (1.5 mm lateral, 1.0 mm posterior to bregma, and 4.5 mm deep from skull surface) under pentobarbital sodium anesthesia (50 mg/kg). The cannulas were anchored to the skull with screws embedded in dental acrylic cement. The free end of each cannula was attached to a Silastic tube filled with artificial CSF (aCSF). The Silastic tubes were tunneled under the skin, exteriorized between the scapulae, and occluded with a metal pin. A polyethylene catheter (PE-10 connected to a PE-50; Clay Adams, Parsippany, NJ) filled with heparinized 0.15 M NaCl solution was then passed into the thoracic aorta via the left femoral artery; the catheter was tunneled under the skin and brought out of the back of the neck. Four days later, the correct placement of the cannulas in the ventricles was tested by determining the dipsogenic response to ANG II (1).
Experimental Protocols
Experiments were started at 9:00 A.M. on the 5th day after implantation of the cerebroventricular cannulas in conscious rats while resting in their home cages. The arterial and cerebroventricular catheters were connected to extension tubings that exited the top of the cage through a small opening. The protocol consisted of stabilization and basal and experimental periods (30 min each). Blood samples (0.2 ml) were collected into tubes containing 20 ~1 EDTA (60 mg/ml) and aprotinin (1,000 U/ml) at the end of the basal period and at the 5th, 15th, and 30th min of the experimental period and were replaced with an equal amount of 0.15 M NaCl. Blood was immediately centrifuged for 5 min in a refrigerated centrifuge, and plasma was separated and stored at -40°C until assay. Infusions and injections (icv) were made with a loo-p1 Hamilton syringe (Hamilton, Reno, NV) connected to a pump (Medical, St. Martin le Vinoux, France) Experiment 1: effect of kinin antagonist and kallikrein antibodies on plasma immunoreactive ACTH levels. Rats were assigned to one of the following icv infusions through the experimental period: 1) aCSF (at the rate of 10 pi/h, n = 8), 2) kinin antagonist (at the rate of 15.4 nmoll0 ~1 aCSF-' l h-l, n = 8), and 3) kallikrein antibodies (at the rate of 13 pmol.10 ~1 aCSF-'* h-l, n = 8). . Each group consisted of two subgroups (n = 9 each) given an infusion of either aCSF (at the rate of 10 pi/h) or kinin antagonist (at the rate of 15.4 nmol.10 ~1 aCSF-' . h-l) during basal and experimental periods via the contralateral cerebroventricular cannula.
Experiment
3: effect of melittin on plasma immunoreactive ACTH levels. Rats were assigned to one of the following icv infusions during basal and experimental periods as follows : 1) aCSF (at the rate of 10 Ill/h, n = 18), 2) kinin antagonist (at the rate of 15.4 nmoll0 ~1 aCSF-l l h-l, n = 18), 3) kallikrein antibodies (at the rate of 13 pmol.10 ~1 aCSF-'. h-l, n = 18), 4) indomethacin (at the rate of 0.28 mmol -10 ~1 aCSF-l . h-l, n = 18), 5) AVP antagonist (at the rate of 17.4 nmoll0 ~1 aCSF-' . h-l, n = 18), and 6) CRF antagonist (at the rate of 5.2 nmol.10 ~1 aCSF-' . h-l, n = 18). Each group was divided into two subgroups (n = 9 each) given icv infusion of either aCSF (at the rate of 10 pi/h) or melittin (at the rate of 7 nmol.10 ~1 aCSF-l* h-l) during the experimental period via the contralatera1 cerebroventricular cannula. At the end of the experimental period, the rats assigned to groups 1 and 3 were anesthetized with pentobarbital(50 mg/kg ip), were transcardially perfused with 0.15 NaCl to remove blood from the pituitary, and were decapitated. The brain was rapidly removed and dissected on ice. The pituitary was isolated, removed, and then processed according to Powers (23) . Briefly, the pituitary was rinsed in 0.15 M NaCl and homogenized in 200 ~1 of 500 mM sodium phosphate buffer (pH 7.5) containing 0.15 M NaCl and 0.1% (wt/vol) Triton X-100 using a microultrasonic cell disrupter (Sonorex; Bandelin Electronic, Berlin, FRG). Homogenates were stored at -40°C until assay. Rats were assigned to one of the following icv infusions during basal and experimental periods as follows: 1) aCSF (at the rate of 10 pi/h, n = 18), and 2) kinin antagonist (at the rate of 15.4 nmol. 10 ~1 aCSF-l . h-l, n =18). Each group was divided into two subgroups (n = 9) given insulin (0.3 IU -0.5 ml 0.15 M NaCl-l. kg body wt-l ia) or vehicle (0.5 ml 0.15 M NaCl/kg body wt ia).
At the end of the experimental period, rats assigned to group 1 underwent the same procedure performed in experiment 3 to isolate pituitary.
Analytic Procedures
Plasma immunoreactive ACTH (irACTH) was determined by a double-antibody immunoradiometric assay specific for ACTH-( l-39) (Nichols Diagnostic Products, San Juan Capistrano, CA) and expressed in picograms per milliliter. The method is sensitive to 1 pg/ml; intra-and interassay variations were 4.8 and 9.1%, respectively. Recovery of ACTH-( l-39) added to plasma samples ranged between 98 and 103%. Antibodies do not cross-react with ACTH-(l-24), ACTH-(ll-24), ACTH-( l&39), ACTH-( l-lo), a-MSH, @-MSH, fl-luteinizing hormone, and p-endorphin.
Glucose concentration was measured on fresh blood using a Reflolux photometer (Boehringer Mannheim, Mannheim, FRG) .
Pituitary homogenates were assayed for protein (13) and glandular kallikrein activity (6) determination. Kallikrein activity in homogenates was measured by an end point method at 37°C in 0.1 M Tris HCl buffer (pH 8.0) containing soybean trypsin inhibitor (Sigma; type 1-S). The reaction was started by adding substrate (D-Val-Leu-Arg-p-nitroanilide; S2266; Kabi Diagnostica, Stockholm, Sweden) to the final concentration of 1.5 mmol/ml. Eight hours later the reaction was stopped by adding 100 ~1 of 50% acetic acid. Using the above procedure, ~10% of the substrate was hvdrolvzed at the end of the incu- bation. Controls consisted of aliquots of the same homogenates incubated without substrate (blanks) or with substrate in the presence of aprotinin (50 U/ml) or glandular kallikrein antibodies (13 pmol/ml). Absorbance of blanks at 405 nm was subtracted from that of homogenates incubated with substrate, and kallikrein activity was expressed as picomoles p-nitroaniline released per second per milligram protein.
Statistical Analysis
Data were expressed as means t SE. Two-way analysis of variance (ANOVA) was used to compare changes in plasma irACTH levels between groups and over time. When this analysis was significant, one-way ANOVA was performed within each group to look at the time effect and for each time period to look at the treatment effect. If one-way ANOVA was significant, then Bonferroni's test was applied to pinpoint where the differences were for either time or treatment factors. Mathematical calculations and statistical analysis were performed with a Statview II package on a Macintosh IICX computer.
RESULTS
Experiment 1: Effect of Kinin Antagonist and Kallikrein Antibodies on Plasma irACTH Levels
Infusion (icv) of either aCSF, kinin antagonist, or kallikrein antibodies did not alter plasma irACTH levels over time [aCSF: from a basal value of 89 t 4 to 92 & 4, 90 t 3, and 85 t 4 pg/ml; kinin antagonist: from a basal value of 94 t 8 to 90 t 8, 92 t 5, and 93 t 4 pg/ml; kallikrein antibodies: from a basal value of 87 t 10 to 85 t 6, 88 $-7, and 90 t 5 pg/ml at 5, 15, and 30 min, respectively; not significant (NS)]. ANOVA did not detect any difference in the irACTH response among groups.
Experiment 2: Specificity of Kinin Antagonist
As shown in Fig. 1 , icv injection of aCSF did not alter plasma irACTH levels in rats pretreated with kinin antagonist or its vehicle (aCSF).
Injection (icv) of bradykinin increased plasma irACTH levels from a basal value of 93 & 4 to 200 t 12,160 t 10, and 140 t 4 pg/ml at 5,15, and 30 min in rats pretreated with vehicle (P < 0.01) but did not alter irACTH in those pretreated with icv kinin antagonist (from a basal value of 98 t 5 to 108 t 6, 102 t 4, and 101 t 3 pg/ml at 5,15, and 30 min, respectively; NS). ANOVA detected a significant difference between the two groups regarding the irACTH response to bradykinin (P < 0.05). Injection (icv) of PGE2, AVP, or CRF increased plasma irACTH levels over time in rats pretreated with icv kinin antagonist or vehicle (P < 0.01). ANOVA did not detect significant differences among groups given kinin antagonist or vehicle regarding the irACTH response to each agonist.
Experiment 3: Effect of Melittin on Plasma irACTH Levels
As shown in Fig. 2 , icv infusion of melittin increased plasma irACTH levels from a basal value of 95 t 4 to 227 t 9, 215 t 11, and 268 t 7 pg/ml in rats pretreated with icv aCSF (P C 0.01). Infusion (icv) of the melittin vehicle (aCSF) during the experimental period did not alter plasma irACTH levels over time in rats pretreated with icv aCSF (from a basal value of 92 t 4 to 94 t 3, 98 t 4, and 94 t 5 pg/ml; NS). The irACTH response to melittin was significantly different from that induced by its vehicle (P < 0.01).
Neither melittin nor its vehicle altered irACTH levels over time in rats pretreated with icv kinin antagonist, kallikrein antibodies, or indomethacin. Infusion (icv) of melittin significantly increased ir-ACTH levels in rats pretreated with antagonists of AVP or CRF (P < 0.01). The irACTH response to melittin in groups given AVP or CRF antagonists was significantly different (P < 0.01) from that induced by melittin vehicle but similar to that caused by melittin in group 1, which was pretreated with icv aCSF. Fig. 3 . Effect of intra-arterial injection of insulin or vehicle (hatched bars) on plasma glucose and irACTH levels in rats pretreated with icv infusion of aCSF (10 pi/h) or BK ANT (15.4 nmol-10 ~1 aCSF-' l h-l). Insulin (0.3 IUO.5 ml 0.15 M NaCl-1 l kg body wt-' ia) was injected at beginning of experimental period (time 0). Artificial CSF or kinin antagonist were infused through basal and experimental periods. Values are means t SE and represent plasma glucose and irACTH levels before (tine 0) and 5, 15, and 30 min after injection of insulin or its vehicle. l P < 0.05 vs. baseline value; t P < 0.05 vs. vehicle. t 0.9 vs. 5.7 t 0.6 pmol s-l. mg protein-'; P < 0.05), despite the fact that it blocked the increase in plasma irACTH levels induced by melittin. Kallikrein activity in pituitary homogenates was completely inhibited by the in vitro addition of aprotinin or antibodies against glandular kallikrein, but it was resistant to soybean trypsin inhibitor. As shown in Fig. 3 , insulin vehicle (saline) did not alter glucose and irACTH levels in rats pretreated with icv kinin antagonist or its vehicle (aCSF).
Insulin reduced plasma glucose levels either in rats pretreated with icv kinin antagonist or its vehicle (P < 0.01). The hypoglycemic response was similar in either group.
Insulin-induced hypoglycemia was accompanied by a significant increase in irACTH levels in both groups. However, the increase in irACTH levels observed in the group pretreated with icv kinin antagonist (10 t 3,40 t 6, and 55 t 5 pg/ml at 5, 15, and 30 min, respectively) was slightly but significantly less in magnitude compared with that found in rats pretreated with icv aCSF (30 t 3, 70 t 5, and 86 t 4 pg/ml at 5, 15, and 30 min, respectively).
Pituitary kallikrein activity was higher in rats given insulin than in the control group given saline (21.2 t 1.3 vs. 5.7 t 0.3 pmol . s-l l mg protein-'; P < 0.05). Kallikrein activity was completely inhibited by the in vitro addition of aprotinin or antibodies against glandular kallikrein, but it was resistant to soybean trypsin inhibitor.
DISCUSSION
In the present study we found that icv administration of an antagonist of kinins or of antibodies against rat glandular kallikrein do not alter plasma irACTH levels in rats. However, both agents prevent the increase in plasma irACTH levels caused by icv melittin, an activator of membrane-bound kallikrein, and the antagonist blunts the irACTH response to insulin-induced hypoglycemia.
The hypothesis that the kallikrein-kinin system plays a role in the regulation of ACTH secretion is inferred from studies showing that exogenous bradykinin stimulates the secretion of POMC-derived peptides both in vitro and in vivo (10, 15, 18) . The recent synthesis of competitive receptor antagonists of bradykinin (33) and the availability of antibodies against rat glandular kallikrein (35) allow a more direct approach to study the physiological role of endogenous kinins. The receptor antagonist of bradykinin used in the present study proved to be specific both in vitro (33) and in vivo (14, 33) . Supplementary evidence regarding the specificity of E316 BRAIN KININS AND ACTH RELEASE the antagonist is provided by our observation that it prevents the ACTH response to icv bradykinin but does not alter the response to AVP, CRF, or PGEZ. Administration (icv) of the antagonist or antibodies against rat glandular kallikrein did not cause any effect on plasma irACTH levels in conscious ovariectomized estrogen-treated rats. These results imply that in this experimental model the kallikrein-kinin system located in circumventricular structures of the brain might not be involved in the regulation of ACTH secretion in basal conditions. On the other hand, we cannot rule out the possibility that the antagonist or kallikrein antibodies have reached concentrations too low to inhibit the kallikrein-kinin system in deeper areas of the brain. Higher doses of antagonist or antibodies may be needed to address this issue. Unfortunately, a dose of antagonist 10 times higher than that used in the present study increases plasma irACTH levels in rats (Madeddu, unpublished observations) . As icv bradykinin stimulates ACTH release, the change in plasma irACTH levels induced by a high dose of antagonist may be due to its residual kinin-like agonistic activity (27, 33) . In addition, icv administration of high doses of antagonist induces behavioral alterations (barrel rotation), which may be attributable to nonspecific pharmacological properties rather than to antagonism of kinins (20) . The limited availability of kallikrein antibodies did not allow us to test whether higher doses are able to affect ACTH release.
Although the kallikrein-kinin system may not be involved in the regulation of ACTH release in basal conditions, it could play a role in the stimulated conditions. Melittin, a peptide able to increase kininogenase activity and kinin levels in dog and rat CSF (30, 36) , stimulated ACTH release from the adenohypophysis in vitro (12). The latter effect was rapid in onset, reversible, concentration related, dependent on the presence of calcium in the incubation medium, and unrelated to the activation by melittin of phospholipase AZ (12). We found that icv infusion of melittin stimulates ACTH release and increases pituitary kallikrein activity in rats. Infusion (icv) of kinin antagonist or kallikrein antibodies prevented, to a similar extent, the increase in plasma irACTH levels induced by melittin. It is conceivable therefore that kallikrein, once activated by melittin, generates kinins in amounts large enough to stimulate the release of ACTH. Because of the icv route of administration, it is likely that kinin antagonist and kallikrein antibodies prevent melittin-induced ACTH release by inhibiting the kallikrein-kinin system in brain areas bathed by the CSF. Although blockade of the kallikrein-kinin system in deeper structures of the brain might also occur, the finding that icv kallikrein antibodies prevent the increase in plasma ACTH levels without affecting pituitary kallikrein activity does not support a contribution of the pituitary kallikrein-kinin system to the effect of melittin on ACTH release. It is unlikely that penetration of the kinin antagonist from the cerebroventricular space into the circulation induced peripheral effects able to block the increase in irACTH caused by melittin. Indeed, the latter effect is not inhibited by intra-arterially infused kinin antagonist (Madeddu, unpublished observations).
Continuous generation of kinins might account for the long-term duration of the irACTH response to melittin, whereas a single icv injection of bradykinin exerts a short-lasting effect probably because of its rapid degradation by endogenous kininases.
We found that indomethacin completely blocks the increase in plasma irACTH levels caused by melittin, whereas it failed to inhibit the release of POMC-derived peptides induced by melittin from rat adenohypophysis in vitro (12). Melittin reportedly stimulates PG synthesis by activating cell membrane phospholipase AZ (17) and icv PGE2 causes ACTH release. Thus PGs might be directly responsible for the effect induced by melittin on ACTH release in vivo. Alternatively, PGs could mediate the effect of kinins on ACTH release. It is known that bradykinin activates PG synthesis (16) and exerts its central cardiovascular effects through the release of PGs (29, 36) . We found that the icv kinin antagonist is able to block the irACTH response to melittin but not that induced by icv administration of PGE,; it is conceivable therefore that brain kinins initiate the ACTH response induced by melittin, but brain PGs are the final mediators.
Failure of AVP or CRF antagonists to prevent the response to melittin may imply that the coordinated activation of the kallikrein-kinin and PG systems stimulates ACTH release by a mechanism independent from CRF and AVP. Okajima and Hertting (18) have shown that bradykinin-induced ACTH release from rat pituitary tissue is delayed and requires higher concentrations of agonist in comparison with that of AVP or CRF. They also reported that the effect of bradykinin is additive to CRF-or AVP-induced ACTH release. In view of these results, they speculated that bradykinin may be a modulator of ACTH secretion rather than a major releasing factor like CRF or AVP.
Insulin has been postulated to stimulate ACTH release acting through peripheral and central pathways, according to the magnitude of hypoglycemia produced (22). It is generally assumed that enhanced secretion of CRF is the main determinant of the ACTH response to hypoglycemia, although other neuropeptides, including AVP, might act as modulatory factors as well (22). We found that the ACTH response induced by mild hypoglycemia can be partially prevented by icv administration of kinin antagonist. Unless the antagonist interacts with other neuropeptide receptors, these results may suggest that brain kinins are modulators of ACTH secretion. Interaction of the antagonist with other unrelated peptides was ruled out in the present study as well as in previous experiments (14); thus it is unlikely that nonspecific effects of the antagonist are responsible for blunting the ACTH response to hypoglycemia.
Either icv melittin or intra-arterial insulin administration caused an increase in pituitary kallikrein activity. We do not know whether this increase was limited to a particular area of the pituitary since kallikrein activity was measured in homogenates without prior lobe dissection. Regarding the mechanism(s) by which pituitary kallikrein activity was augmented, one might speculate that de novo synthesis of the enzyme was stimulated
